Royalty Pharma PLC $RPRX is Regal Partners Ltd’s 9th Largest Position

Regal Partners Ltd decreased its position in Royalty Pharma PLC (NASDAQ:RPRX) by 6.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,345,196 shares of the biopharmaceutical company’s stock after selling 90,760 shares during the period. Royalty Pharma accounts for about 4.0% of Regal Partners Ltd’s investment portfolio, making the stock its 9th biggest position. Regal Partners Ltd owned approximately 0.24% of Royalty Pharma worth $48,467,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of RPRX. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Royalty Pharma by 69.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,360 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 6,700 shares during the period. Amalgamated Bank boosted its holdings in shares of Royalty Pharma by 4.4% in the first quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company’s stock valued at $636,000 after purchasing an additional 866 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Royalty Pharma by 48.3% in the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 41,798 shares of the biopharmaceutical company’s stock valued at $1,301,000 after purchasing an additional 13,615 shares during the period. Keybank National Association OH boosted its holdings in shares of Royalty Pharma by 16.6% in the first quarter. Keybank National Association OH now owns 32,818 shares of the biopharmaceutical company’s stock valued at $1,022,000 after purchasing an additional 4,666 shares during the period. Finally, GF Fund Management CO. LTD. raised its stake in Royalty Pharma by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 11,377 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 2,048 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RPRX. Morgan Stanley reduced their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Citigroup boosted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. Wall Street Zen raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, The Goldman Sachs Group began coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $46.00.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $37.54 on Friday. The business’s fifty day simple moving average is $36.19 and its 200-day simple moving average is $35.22. The company has a market cap of $21.89 billion, a PE ratio of 21.70, a PEG ratio of 2.06 and a beta of 0.60. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74. Royalty Pharma PLC has a 12-month low of $24.05 and a 12-month high of $38.00.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. Analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.3%. Royalty Pharma’s dividend payout ratio is presently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.